First Author: C.Ünlü TURKEY
Co Author(s): G. Erdogan T. Aydogan E. Guney Kardes B.I. Sezgin Akcay T.K. Bozkurt 0 0 0 0 0 0 0 0 0
Back to previous
To evaluate the subfoveal choroidal thickness (SFCT) changes after intravitreal bevacizumab (IVB) therapy for central serous chorioretinopathy (CSC) by using enhanced depth imaging spectral-domain optical coherence tomography (EDI-OCT).
Istanbul Umraniye Education and Research Hospital, Ophthalmology Department
We assessed the medical records of the central serous chorioretinopathy patients who received intravitreal bevacizumab (1,25 mg/0,05 ml) (IVB group) or who were observed without intervention (control group). SFCT was measured by using EDI OCT. Main outcome measure was the change in SFCT.
There were 21 patients (21 eyes) in the IVB group and 16 patients (16 eyes) in the control group. All patients showed total or near total resolution of neurosensory detachment and improvement in visual acuity. In the IVB group, the mean subfoveal choroidal thickness was 315±57 µm at baseline visit and decreased to 296±53 µm at final visit. In the control group, the mean subfoveal choroidal thickness was 307±51 µm at baseline visit and decreased to 266±41 µm at final visit. Although there was a significant decrease in mean subfoveal choroidal thickness for the control group, there was not a significant decrease for the IVB group (41 µm vs. 19 µm, p=0,003 vs p=0,071). No ocular or systemic complications related to IVB injection occured during follow-up.
SFCT decreased in both groups with remission of the disease. However the decrease was significantly greater in the control group than in the IVB group. In terms of anatomic and functional outcomes, IVB injection in CSC was not promising.